The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Chemokines and the immune response to cancer
Open accessAbstract
SUMMARY Chemokines are chemotactic cytokines that regulate the migration of immune cells. Chemokines function as cues for the coordinated recruitment of immune cells into and out of tissue and also guide the spatial organization and cellular interactions of immune cells within tissues. Chemokines are critical in directing immune cell migration necessary to mount and then deliver an effective anti-tumor immune response; however, chemokines also participate in the generation and recruitment of immune cells that contribute to a pro-tumorigenic microenvironment. Here, we review the role of the chemokine system in anti-tumor and pro-tumor immune responses and discuss how malignant cells and the tumor microenvironment regulate the overall chemokine landscape to shape the type and outcome of immune responses to cancer and cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120145 · Cited by 2,059
Self-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
Identification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,495
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-A. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C. D., Levine, J. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.014 · Cited by 1,209
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Self-citationMlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,026
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 817
Neutrophil plasticity in the tumor microenvironment
Giese, M. A., Hind, L. E., & Huttenlocher, A. (2019) · Blood · doi:10.1182/blood-2018-11-844548 · Cited by 783
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716
Self-citationRadiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3099 · Cited by 711
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. (2016) · Nature · doi:10.1038/nature19317 · Cited by 677
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 650
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629
KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression
Seifert, L., Werba, G., Tiwari, S., Giao Ly, N. N., Alothman, S., Alqunaibit, D., Avanzi, A., Barilla, R., Daley, D., Greco, S. H., et al. (2016) · Nature · doi:10.1038/nature17403 · Cited by 611
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Cascone, T., McKenzie, J. A., Mbofung, R. M., Punt, S., Wang, Z., Xu, C., Williams, L. J., Wang, Z., Bristow, C. A., Carugo, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.024 · Cited by 611
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
Keklikoglou, I., Cianciaruso, C., Güç, E., Squadrito, M. L., Spring, L. M., Tazzyman, S., Lambein, L., Poissonnier, A., Ferraro, G. B., Baer, C., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0256-3 · Cited by 530
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Self-citationSoucek, L., Lawlor, E. R., Soto, D., Shchors, K., Swigart, L. B., & Evan, G. I. (2007) · Nature Medicine · doi:10.1038/nm1649 · Cited by 507
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
Liang, H., Deng, L., Hou, Y., Meng, X., Huang, X., Rao, E., Zheng, W., Mauceri, H., Mack, M., Xu, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01566-5 · Cited by 488
Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity
Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3132 · Cited by 485
Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 485
Self-citationFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
Dorner, B. G., Dorner, M. B., Zhou, X., Opitz, C., Mora, A., Güttler, S., Hutloff, A., Mages, H. W., Ranke, K., Schaefer, M., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.027 · Cited by 456
Gubin, M. M., Esaulova, E., Ward, J. P., Malkova, O. N., Runci, D., Wong, P., Noguchi, T., Arthur, C. D., Meng, W., Alspach, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.030 · Cited by 419
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A. Y., Na, M., Dyson, K. A., Grippin, A. J., Deleyrolle, L. P., Zhang, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11869-4 · Cited by 385
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
Boissonnas, A., Fetler, L., Zeelenberg, I. S., Hugues, S., & Amigorena, S. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061890 · Cited by 377
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Villablanca, E. J., Raccosta, L., Zhou, D., Fontana, R., Maggioni, D., Negro, A., Sanvito, F., Ponzoni, M., Valentinis, B., Bregni, M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2074 · Cited by 335
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene
Borrello, M. G., Alberti, L., Fischer, A., Degl'Innocenti, D., Ferrario, C., Gariboldi, M., Marchesi, F., Allavena, P., Greco, A., Collini, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503039102 · Cited by 331
Mlecnik, B., Tosolini, M., Charoentong, P., Kirilovsky, A., Bindea, G., Berger, A., Camus, M., Gillard, M., Bruneval, P., Fridman, W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.057 · Cited by 328
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 327
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Kalbasi, A., Komar, C., Tooker, G. M., Liu, M., Lee, J. W., Gladney, W. L., Ben-Josef, E., & Beatty, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0870 · Cited by 305
Beatty, G. L., Winograd, R., Evans, R. A., Long, K. B., Luque, S. L., Lee, J. W., Clendenin, C., Gladney, W. L., Knoblock, D. M., Guirnalda, P. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.010 · Cited by 293
The atypical chemokine receptor CCRL1 shapes functional CCL21 gradients in lymph nodes
Ulvmar, M. H., Werth, K., Braun, A., Kelay, P., Hub, E., Eller, K., Chan, L., Lucas, B., Novitzky-Basso, I., Nakamura, K., et al. (2014) · Nature Immunology · doi:10.1038/ni.2889 · Cited by 290
Bronger, H., Singer, J., Windmüller, C., Reuning, U., Zech, D., Delbridge, C., Dorn, J., Kiechle, M., Schmalfeldt, B., Schmitt, M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.172 · Cited by 274
Nagarsheth, N., Peng, D., Kryczek, I., Wu, K., Li, W., Zhao, E., Zhao, L., Wei, S., Frankel, T., Vatan, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1938 · Cited by 271
Rapp, M., Wintergerst, M. W. M., Kunz, W. G., Vetter, V. K., Knott, M. M. L., Lisowski, D., Haubner, S., Moder, S., Thaler, R., Eiber, S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20170277 · Cited by 271
Wu, Q., Zhou, W., Yin, S., Zhou, Y., Chen, T., Qian, J., Su, R., Hong, L., Lu, H., Zhang, F., et al. (2019) · Hepatology · doi:10.1002/hep.30593 · Cited by 269
Arwert, E. N., Harney, A. S., Entenberg, D., Wang, Y., Sahai, E., Pollard, J. W., & Condeelis, J. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.007 · Cited by 263
Lim, J. Y. H., Gerber, S. A., Murphy, S. P., & Lord, E. M. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1506-7 · Cited by 257
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
Mlecnik, B., Van den Eynde, M., Bindea, G., Church, S. E., Vasaturo, A., Fredriksen, T., Lafontaine, L., Haicheur, N., Marliot, F., Debetancourt, D., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx123 · Cited by 250
CCR8+FOXp3+Tregcells as master drivers of immune regulation
Barsheshet, Y., Wildbaum, G., Levy, E., Vitenshtein, A., Akinseye, C., Griggs, J., Lira, S. A., & Karin, N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621280114 · Cited by 249
Hong, M., Puaux, A.-L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., Prévost-Blondel, A., Avril, M.-F., Nardin, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1466 · Cited by 246
Chao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 246
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
Bauer, C. A., Kim, E. Y., Marangoni, F., Carrizosa, E., Claudio, N. M., & Mempel, T. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66375 · Cited by 238
Wang, D., Yang, L., Yu, W., Wu, Q., Lian, J., Li, F., Liu, S., Li, A., He, Z., Liu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0701-2 · Cited by 234
Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W. W., Lizée, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0712 · Cited by 222
Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer
Faget, J., Groeneveld, S., Boivin, G., Sankar, M., Zangger, N., Garcia, M., Guex, N., Zlobec, I., Steiner, L., Piersigilli, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.052 · Cited by 222
Hickman, H. D., Reynoso, G. V., Ngudiankama, B. F., Cush, S. S., Gibbs, J., Bennink, J. R., & Yewdell, J. W. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.009 · Cited by 217
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
Di Pilato, M., Kim, E. Y., Cadilha, B. L., Prüßmann, J. N., Nasrallah, M. N., Seruggia, D., Usmani, S. M., Misale, S., Zappulli, V., Carrizosa, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1215-2 · Cited by 210
CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors
Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205
Tumor-induced stromal reprogramming drives lymph node transformation
Riedel, A., Shorthouse, D., Haas, L., Hall, B. A., & Shields, J. (2016) · Nature Immunology · doi:10.1038/ni.3492 · Cited by 204
Atypical Chemokine Receptors and Their Roles in the Resolution of the Inflammatory Response
Bonecchi, R., & Graham, G. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00224 · Cited by 189
CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117534 · Cited by 178
Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer
Wang, L., Simons, D. L., Lu, X., Tu, T. Y., Solomon, S., Wang, R., Rosario, A., Avalos, C., Schmolze, D., Yim, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0429-7 · Cited by 174
Vetrano, S., Borroni, E. M., Sarukhan, A., Savino, B., Bonecchi, R., Correale, C., Arena, V., Fantini, M. C., Roncalli, M. G., Malesci, A., et al. (2009) · Gut · doi:10.1136/gut.2009.183772 · Cited by 162
Mondini, M., Loyher, P.-L., Hamon, P., de Thoré, M. G., Laviron, M., Berthelot, K., Clémenson, C., Salomon, B. L., Combadière, C., Deutsch, É., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0633 · Cited by 154
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Catani, J. P. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 149
Functional reprogramming of regulatory T cells in the absence of Foxp3
Charbonnier, L.-M., Cui, Y., Stephen-Victor, E., Harb, H., Lopez, D., Bleesing, J. J., Garcia-Lloret, M. I., Chen, K., Ozen, A., Carmeliet, P., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0442-x · Cited by 145
Targeting the ATF4 pathway in cancer therapy
Singleton, D. C., & Harris, A. L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.728207 · Cited by 142
The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth
Shen, H., Schuster, R. M., Stringer, K. F., Waltz, S. E., & Lentsch, A. B. (2006) · The FASEB Journal · doi:10.1096/fj.05-4764com · Cited by 140
Frankenberger, C. A., Rabe, D. C., Bainer, R. O., Sankarasharma, D., Chada, K. K., Krausz, T. N., Gilad, Y., Becker, L., & Rosner, M. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3394 · Cited by 140
Mukaida, N., Sasaki, S., & Baba, T. (2014) · Mediators of Inflammation · doi:10.1155/2014/170381 · Cited by 136
A silent chemokine receptor regulates steady-state leukocyte homing in vivo
Heinzel, K., Benz, C., & Bleul, C. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608274104 · Cited by 127
Sharma, M. D., Rodríguez, P. C., Koehn, B. H., Baban, B., Cui, Y. R., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.014 · Cited by 127
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 120
Yang, J., Yan, C. W., Vilgelm, A. E., Chen, S., Ayers, G. D., Johnson, C. A., & Richmond, A. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0312 · Cited by 120
Siddiqui, I., Erreni, M., van Brakel, M., Debets, R., & Allavena, P. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0125-1 · Cited by 119
CXCR3 enables recruitment and site-specific bystander activation of memory CD8(+) T cells
Maurice, N. J., McElrath, M. J., Andersen-Nissen, E., Frahm, N., & Prlic, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12980-2 · Cited by 117
Lieber, S., Reinartz, S., Raifer, H., Finkernagel, F., Dreyer, T. F., Bronger, H., Jansen, J. M., Wagner, U. A. G., Worzfeld, T., Müller, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424672 · Cited by 113
Juric, V., O’Sullivan, C., Stefanutti, E., Kovalenko, M. A., Greenstein, A. E., Barry-Hamilton, V., Mikaelian, I., Degenhardt, J. D., Peng, Y., Smith, V., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207255 · Cited by 110
Steinberg, S. M., Shabaneh, T. B., Zhang, P., Martyanov, V., Li, Z., Malik, B. T., Wood, T. A., Boni, A., Molodtsov, A. K., Angeles, C. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1755 · Cited by 105
Kerdidani, D., Chouvardas, P., Rocañín-Arjó, A., Giopanou, I., Ntaliarda, G., Guo, Y. A., Tsikitis, M., Kazamias, G. M., Potaris, Κ., Stathopoulos, G. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09370-z · Cited by 104
Vergani, E., Guardo, L. D., Dugo, M., Rigoletto, S., Tragni, G., Ruggeri, R., Perrone, F., Tamborini, E., Gloghini, A., Arienti, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6599 · Cited by 102
CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer
Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X.-H., Yang, X., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005869 · Cited by 101
Gubin, M. M., Esaulova, E., Ward, J. P., Malkova, O. N., Runci, D., Wong, P., Noguchi, T., Arthur, C. D., Meng, W., Alspach, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.003 · Cited by 98
Sun, J. T., Sun, J., Song, B., Zhang, L., Shao, Q., Liu, Y., Yuan, D., Zhang, Y., & Qu, X. (2016) · Scientific Reports · doi:10.1038/srep35855 · Cited by 95
Tumors vs. Chronic Wounds: An Immune Cell's Perspective
Hua, Y., & Bergers, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02178 · Cited by 88
IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development
Li, A., Herbst, R. H., Canner, D. A., Schenkel, J. M., Smith, O. C. G., Kim, J. Y., Hillman, M., Bhutkar, A. J., Cuoco, M. S., Rappazzo, C. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.120 · Cited by 88
Rapp, M., Grassmann, S. A., Chaloupka, M., Layritz, P., Krüger, S., Ormanns, S., Rataj, F., Janssen, K., Endres, S., Anz, D., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1105428 · Cited by 87
Lian, J., & Luster, A. D. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.05.003 · Cited by 84
Self-citationIncreasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes
Connolly, K. A., Belt, B. A., Figueroa, N. M., Murthy, A., Patel, A. P., Kim, M., Lord, E. M., Linehan, D. C., & Gerber, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13287 · Cited by 79
Idorn, M., Skadborg, S. K., Kellermann, L., Halldórsdóttir, H. R., Olofsson, G. H., Met, Ö., & Straten, P. T. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1450715 · Cited by 78
Bryce, S. A., Wilson, R. A. M., Tiplady, E. M., Asquith, D. L., Bromley, S. K., Luster, A. D., Graham, G. J., & Nibbs, R. J. B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501542 · Cited by 71
Self-citationThe role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients
Zhang, C., Qi, Y., Li, X., Yang, Y., Liu, D., Zhao, J., Zhu, D., Wu, K., Zhou, X., & Zhao, S. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.12.008 · Cited by 69
Rafat, M., Aguilera, T. A., Vilalta, M., Bronsart, L. L., Soto, L. A. C., von Eyben, R., Golla, M. A., Ahrari, Y., Melemenidis, S., Afghahi, A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3623 · Cited by 57
Chang, K., Wu, C., Fang, K., Tsai, C., Chang, Y., Liu, S.-C., & Kao, H. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.05.006 · Cited by 52
Regulation of Chemokine Function: The Roles of GAG-Binding and Post-Translational Nitration
Thompson, S., Martínez‐Burgo, B., Sepuru, K. M., Rajarathnam, K., Kirby, J. A., Sheerin, N., & Ali, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081692 · Cited by 52
Liu, B., Chen, P., Xi, D., Zhu, H., & Gao, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.08.031 · Cited by 50
Qian, L., Yu, S., Yin, C., Zhu, B., Chen, Z., Meng, Z., & Wang, P. (2019) · Pancreatology · doi:10.1016/j.pan.2019.01.015 · Cited by 49
Breathing New Life Into Hypoxia-Targeted Therapies for Non–Small Cell Lung Cancer
Lin, S. H., & Koong, A. C. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx163 · Cited by 45
Xu, L., Xu, W., Wen, Z., & Xiong, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020282 · Cited by 28
Hsin, L., Kao, H., Chen, I., Tsang, N., Hsu, C., Liu, S.-C., Chang, Y., & Chang, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080052 · Cited by 26
Liu, W., Liu, Y., Fu, Q., Zhou, L., Chang, Y., Xu, L., Zhang, W., & Xu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7468 · Cited by 25
Chiodoni, C., Cancila, V., Renzi, T. A., Perrone, M., Tomirotti, A., Sangaletti, S., Botti, L., Dugo, M., Milani, M., Bongiovanni, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1425 · Cited by 19
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 458
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Metadata
- Authors
- Ozga, A. J., Chow, M. T., & Luster, A. D.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 54
- Issue
- 5
- Pages
- 859-874
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W3156068899
- Cited by
- 830
- References
- 143
- FWCI
- 37.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.